/ /

  • linkedin
  • Increase Font
  • Sharebar

    Intracameral prostaglandin analogue therapy delivers durable benefit

    Analysis: Nine months after single dose in ongoing trial, potential for once-a-year therapy

    An extended-release intracameral implant loaded with travoprost (travoprost XR; ENV515, Envisia Therapeutics) was found to be well tolerated and effective for providing sustained IOP-lowering, according to 9-month interim analysis findings in an ongoing phase II trial.

    Sponsored: Join us for upscale dinner and engaging discussion on diabetic eye disease at RWC in Ft. Lauderdale!

    The study included 5 patients with bilateral ocular hypertension or open-angle glaucoma previously treated with a topical prostaglandin analogue (PGA). They received a single dose of a low-dose formulation of the travoprost XR implant in one eye and used topical timolol maleate ophthalmic solution 0.5% contralaterally, twice daily.

    In October 2016, Envisia Therapeutics announced that in an interim analysis, the investigational product provided clinically meaningful reduction in IOP throughout 9 months of follow-up.

    The magnitude of the effect was comparable to that achieved prior to the study with topical prostaglandin treatment and during the study with topical timolol treatment in the fellow eye of the same patients.

    Related: Poor oral health may be associated with POAG

    Anecdotally, the IOP-lowering effect with the travoprost intracameral implant has been maintained beyond the 9-month assessment and without loss of clinical efficacy, noted Thomas Walters, MD, study investigator and medical director, Keystone Research, Austin, TX.

    “The ongoing efficacy of this intracameral implant is quite remarkable, and safety data indicate that it minimizes or avoids several of the side effects associated with the topical administration of a prostaglandin,” he said. “Namely, hyperemia seems to be reduced compared to daily topical PGA therapy.

    More: Roles of Klotho and Endothelin-1 in pseudoexfoliation

    “The experience is still very preliminary, but suggests this product has the potential to be a big game-changer in medical therapy for ocular hypertension and glaucoma by taking patient compliance with daily drops out of the equation,” he added.

    Prior to washout of existing IOP-lowering medications, the 5 patients included in the study were using topical latanoprost 0.005% or travoprost 0.004%. Their mean IOP measured at 8 a.m. while on pre-study medication was 19.7 mm Hg and was 26.1 mm Hg after washout.

    The travoprost XR implant was already observed to have an IOP-lowering effect when the first measurement was taken on Day 3. At 9 months, mean IOP was reduced by 6.7 ± 3.8 mm Hg (-26%) from the post-washout level.

    Recent: Tracking treatment adherence in newly diagnosed open-angle glaucoma

    “Because of the steady release of travoprost from the delivery system, the intracameral implant also controls diurnal fluctuations in IOP better than topical therapy,” Dr. Walters said.

    Dr. Walters noted there is some anterior chamber inflammation for about 2 days after the implantation procedure, which is due in part to the use of povidone-iodine for sterile preparation.

    “After that resolves, the eyes have been very white and the anterior chamber quiet,” he said. “Problems that patients had in association with topical prostaglandin use prestudy, such as blurred vision and conjunctival hyperemia, largely abated.”

    More about the procedure

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results